European Journal of Cancer
Volume 41, Issue 17 , Pages 2592-2594 , November 2005

Getting there? Salvage therapy for refractory Langerhans cell histiocytosis in children

  • Sheila Weitzman, MB

      Affiliations

    • Department of Haematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ont, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1 416 813 8886; fax: +1 416 813 5327.
  • Jon Pritchard, FRCPCH

      Affiliations

    • Department of Haematology/Oncology, Royal Hospital for Sick Children, Edinburgh, UK

Received 1 July 2005 ,Accepted 5 July 2005.

References 

  1. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002;39:581–585
  2. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138:728–734
  3. The French LCH Study Group. A multicentre retrospective survey of LCH: 348 cases observed between 1983 and 1993. Arch Dis Child 1996, 75, 17–24.
  4. Ladisch S, Gadner H, Aricó M, et al. A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:107–110
  5. Ceci A, de Terlizzi M, Colella R, et al. Etoposide in recurrent childhood Langerhans’ cell histiocytosis: an Italian cooperative study. Cancer. 1988;62:2528–2531
  6. Mahmoud H, Wang W, Murphy S. Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood. 1991;77:721–725
  7. Egeler RM, de Kraker J, Voûte PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993;21:265–270
  8. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Haematol Oncol Clin N Am. 1998;12:339–357
  9. Saven A, Foon K, Piro L. 2-Chlorodeoxyadenosine induced complete remissions in Langerhans cell histiocytosis. Ann Intern Med. 1994;21:430–432
  10. Saven A, Burian C. Cladribine activity in adult Langerhans cell histiocytosis. Blood. 1999;93:4125–4130
  11. Stine KC, Saylors RL, Willimas LL, et al. 2-Chorodeoxyadenosine(2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288–292
  12. Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol. 2002;69:179–184
  13. Minkov M, Grois N, Broadbent V, et al. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis. Med Pediatr Oncol. 1999;33:482–485
  14. Weitzman S, Arceci R, Braier J, et al. 2-Chlorodeoxyadenosine (2-CDA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of LCH-S-98. Pediatr Blood Cancer. 2005;45:95
  15. Choi SW, Bangaru BS, Wu CD, et al. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine. J Pediatr Hematol Oncol. 2003;25:503–506
  16. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood. 1996;87:256–264
  17. Crews KR, Gandhi V, Srivastava DK, et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002;20:4217–4224
  18. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2-deoxyadenosine (CdA) in cerebrospinal fluid(CSF). Blood. 1992;80:
  19. Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol. 2001;18:199–204
  20. Ottaviano F, Finlay JL. Diabetes Insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol/Oncol. 2003;25:575–577
  21. Kelly KM, Pritchard J. Monoclonal antibody therapy in Langerhans cell histiocytosis-feasible and reasonable?. Br J Cancer. 1994;23(Suppl.):S54–S55
  22. Perreault C, Pelletier M, Landry D, et al. Study of Langerhans cells after allogeneic bone marrow transplantation. Blood. 1984;63:807–811
  23. Weitzman S, McClain K, Arceci R. Treatment of relapsed and/or refractory Langerhans cell histiocytosis. In:  Weitzman S,  Egeler RM editor. Histiocytic Disorders of Children and Adults. Cambridge: Cambridge University Press; 2005;p. 254–271
  24. Donadieu J, Piguet F, Bernard M, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:770–776

PII: S0959-8049(05)00608-8

doi: 10.1016/j.ejca.2005.07.008

European Journal of Cancer
Volume 41, Issue 17 , Pages 2592-2594 , November 2005

Article Tools